AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
The Chinese company will start the first of four pivotal trials of its PD-L1 ADC in April.
Talapro-3 could help move Talzenna into earlier prostate cancer.
Single, double and even triple-payload ADCs will be presented at the meeting.
The company reveals its anti-GPRC5D T-cell engager.
First human data on MK-2010 are imminent.
